Autolus gains on Phase 2 data presentation on leukemia therapy

Autolus Therapeutics (NASDAQ:AUTL) added ~7% pre-market Friday after announcing that Phase 2 data for its CAR T cell therapy obe-cel (AUTO1) will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
As previously disclosed, the company said that obe-cel reached the primary endpoint in the pivotal FELIX study for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL).
Supporting its claim, the company said that in a group of 94 patients who received obe-cel, 76% achieved complete response (CR) or CR with incomplete hematological recovery, according to topline data from the trial.
Meanwhile, at 9.5 months of median follow-up, 61% of responders showed ongoing remission without new anti-cancer drugs.
In terms of safety, 3% (3/94) and 7% (7/94) patients experienced Grade ≥3 cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, respectively.
Autolus (AUTL) is planning to submit a biologics license application for obe-cel towards the end of the year.

More on Autolus